Fig. 1.

TMEM16A/ANO1 mRNA and protein are up-regulated in pancreatic cancer and associated to an enrichment of genes involved in EGFR signaling pathways. (A) Immunohistochemical staining of TMEM16A protein in normal and cancerous pancreatic tissues (data obtained from the Human Protein Atlas http://www.proteinatlas.org/). (A width, 1 mm; A, Insets width, 300 µm.) (B) RNA-sequencing measurement of TMEM16A/ANO1 mRNA expression expressed as log₂ transcript per million (TPM) in normal pancreas and in pancreatic cancer (data obtained from GTEx and TCGA consortium, respectively). ***P < 0.001. (C) Density plot of TMEM16A/ANO1 mRNA expression in normal and cancerous pancreatic tissues. Pancreatic cancer samples with a normalized log₂ value of TMEM16A/ANO1 mRNA expression superior to 11 were defined as high TMEM16A. (D) Overall survival probability curve for patients with pancreatic tumors with low or high expression of TMEM16A. (E) Heatmap of DEGs between pancreatic cancer with low or high TMEM16A expression (42 and 136 samples, respectively). (F) Representation of the ErbB pathway on which genes (nodes) are mapped with log₂(FC) intensity (color) and negative log₁₀ of adjusted P value (size) obtained from the differential expression analysis between pancreatic cancer with low or high TMEM16A expression.